North America Early Toxicity Testing Market

North America Early Toxicity Testing Market Size (2023 to 2028):

The size of the North America Early Toxicity Testing Market was worth USD 315.29 Million in 2023. It is expected to reach USD 460.49 Million by 2028, growing at a CAGR of 7.87% between 2023 to 2028.

Extensive usage of early toxicity testing for various products such as cosmetics, food additives, chemicals, pesticides, and drugs and vaccines are majorly promoting the growth of the market. The government's measures are spending more on research and development of in-vitro and in-silico techniques due to opposition of animal rights organization for the usage of in vivo techniques for toxicity tests is also likely to bolster the demand of the market.

Strict government rules of North American countries for the product approvals and launch of new devices and lengthy processes for the approval are to hamper the growth. Adverse side-effects like irritation on the skin and deficit of consciousness regarding toxicity are to obstruct the change. The scarcity of skilled and experienced professionals and software that can handle multiple sets of data quickly is restricting the growth of the region.

This research report on the North America Early Toxicity Testing Market has been segmented and sub-segmented into the following categories:

By Technique: 

• In-vitro
• In-vivo
• In-Silico

By Assays: 

• Cell-Based ELISA and Western Blots
• Enzyme Toxicity Assays
• Receptor Binding Assays
• Bacterial Toxicity Assays
• Tissues Culture Assays
• Other Assays

By End-user: 

• Pharmaceutical
• Food and Beverages
• Chemical Global Industry
• Diagnostics
• Cosmetics
• Others

By Country:

• The United States
• Canada
• Rest of North America

Regionally, the North America is expected to have the largest share globally during the forecast period and accounted for a market share of 45% in 2019. It is due to the rise in the healthcare infrastructure, favorable government funds in the healthcare sector, and the presence of large pharmaceutical companies in this region.

The U.S. is considered to dominate the early toxicity testing market in the region owing to an increase in research and development activities regarding drug discovery, extensive and simple availability of toxicity testing devices, and products propelling the market growth. Continuous advancements in technology and some of the agencies like the National Institutes of Health and Defense Advanced Research Projects Agency are among the agencies involved in producing funds for drug discovery research and enhancing the acquisition of substitute modes of toxicology testing in the United States. In April 2018, the U.S. Environmental Protection Agency announced a draft policy describing the usage of in-vitro methods to reduce animal usage in testing chemicals inducing skin burning or excitation.

Canada is expected to have notable growth in the region due to the endorsement of in-vitro toxicology and computational methods, hence stimulating its market growth.

Prominent Companies leading the North America Early Toxicity Testing Market Profiled in the Report are Covance, Thermo Fisher Scientific, Quest Diagnostics Corporation, Agilent Technologies, Sigma Aldrich, BD Biosciences, Bio-Rad, Gene Logic, Accelrys, and Charles River Laboratories.